查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1813858

美國胜肽治療（零售端）市場規模、佔有率和趨勢分析報告：按肽類型、適應症、給藥途徑、治療藥物類型、分銷管道和細分市場進行預測，2025 年至 2033 年

U.S. Peptide Therapeutics (Retail Side) Market Size, Share & Trends Analysis Report By Peptide Type, By Indication, By Route of Administration, By Therapeutics Type, By Distribution Channel, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 165 Pages | 商品交期: 2-10個工作天內

價格

美國胜肽療法（零售）市場摘要

預計 2024 年美國胜肽療法（零售）市場規模為 1,036.6 億美元，到 2033 年將達到 3,361.2 億美元，2025 年至 2033 年的複合年成長率為 12.77%。

這些疾病在兒童中的發生率不斷上升，再加上它們在低收入社區中的廣泛發生，凸顯了對負擔得起且有效的治療方案的需求。這些疾病在兒童中的發生率不斷上升，再加上它們在低收入社區中的廣泛發生，凸顯了對負擔得起且有效的治療方案的需求。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 相關/輔助市場展望
  • 市場趨勢與展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 法律規範
  • 商業環境分析工具
    • 產業分析-波特五力分析
    • PESTEL分析
  • 線上線下通路定價分析
  • 消費者對胜肽療法的認知趨勢
  • 直接面對消費者 (DTC)經營模式的影響

第4章 胜肽類業務分析

  • 美國胜肽治療學（零售市場）：胜肽類型變化分析
  • 美國胜肽治療學（零售市場）：胜肽類型細分儀表板
  • 2024 年和 2033 年胜肽類型趨勢和市場佔有率分析
  • 依胜肽類型
  • GLP-1胜肽
  • 健康/長壽/健康生命胜肽
  • 用於其他急性或慢性疾病的胜肽

第5章治療藥物類型業務分析

  • 美國胜肽治療學（零售市場）：治療類型的變化分析
  • 美國胜肽療法（零售市場）：按治療類型細分儀表板
  • 2024 年和 2033 年治療類型趨勢和市場佔有率分析
  • 按治療類型
  • 創新（品牌）胜肽
  • 生物類似胜肽
  • 非專利肽

第6章 指示業務分析

  • 美國胜肽治療學（零售市場）：適應症波動分析
  • 美國胜肽治療學（零售市場）：適應症細分儀表板
  • 2024 年和 2033 年適應症趨勢和市場佔有率分析
  • 按指示
  • 2型糖尿病
  • 肥胖/體重管理
  • 神經內分泌腫瘤
  • 肢端肥大症
  • 生長激素缺乏症
  • 攝護腺癌
  • 骨質疏鬆症
  • 乳癌（荷爾蒙敏感性）
  • 子宮內膜異位症
  • 其他

7. 管理路線業務分析

  • 美國胜肽治療學（零售市場）：給藥途徑變化分析
  • 美國胜肽療法（零售市場）：給藥途徑細分儀表板
  • 2024 年和 2033 年給藥途徑趨勢和市佔率分析
  • 給藥途徑
  • 口服
  • 腸外
  • 經皮
  • 鼻腔
  • 其他給藥途徑

第8章通路業務分析

  • 美國胜肽治療學（零售市場）：分銷管道波動分析
  • 美國胜肽治療（零售）市場：分銷通路細分儀表板
  • 2024年及2033年通路趨勢與市佔率分析
  • 按分銷管道
  • 線下藥局
    • 線下零售藥局市場，2021-2033
    • 連鎖藥局
    • 專業零售藥局
    • 獨立社區藥房
  • 網路藥局/遠端醫療
    • 2021-2033年網路藥局/遠端醫療市場
  • 其他（胜肽專科門診）

第9章 競爭態勢

  • 公司分類（線下藥局）
  • 公司分類（網路藥局）
  • 公司分類（荷爾蒙診所）
  • 參與企業概況
    • Offline Pharmacies
    • Online Pharmacies
    • Specialized Hormone Clinics
  • 企業市場分析
  • 戰略地圖
    • 區域擴張
    • 併購
    • 其他
  • 公司簡介/上市公司
  • Offline Pharmacies
    • CVS Health
    • Walgreens Boots Alliance, Inc.
    • Walmart Pharmacy
    • Rite Aid Corp
    • The Kroger Co.
    • Albertsons
    • Publix
    • Costco Wholesale Corporation
    • Meijer, Inc.
  • Online Pharmacies
    • Hims & Hers Health, Inc
    • Ro (Roman Health Ventures Inc.)
    • Lemonaid Health, Inc.
    • Mark Cuban Cost Plus Drug Company, PBC
    • Amazon.com, Inc.
    • Blink Health Administration LLC, Inc.
    • GoodRx, Inc
    • Honeybee Health Inc.
    • TruePill (acquired by LetsGetChecked in October 2024)
    • AgelessRx
  • Specialized Hormone Clinics
    • Defy Medical
    • Renew Vitality
    • Victory Men's Health
    • Hone Health
    • Joi & Blokes
    • Ways2Well
Product Code: GVR-4-68040-700-6

U.S. Peptide Therapeutics (Retail Side) Market Summary

The U.S. peptide therapeutics (retail side) market size was estimated at USD 103.66 billion in 2024 and is expected to reach USD 336.12 billion by 2033, growing at a CAGR of 12.77% from 2025 to 2033. The increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, highlights the need for affordable and effective treatment options. In addition, the increasing number of pediatric patients affected by these conditions, coupled with their widespread occurrence in low-income regions, underscores the need for affordable and effective treatment options.

U.S. Peptide Therapeutics (Retail Side) Market Report Segmentation

This report forecasts revenue growth at country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033 For this study, Grand View Research has segmented the U.S. peptide therapeutics (retail side) market report based on peptide type, therapeutics type, indication, route of administration, and distribution channel:

  • Peptide Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • GLP-1 Peptides
  • Wellness/Longevity/Healthspan Peptides
  • Peptides for Other Acute or Chronic Medical Conditions
  • Therapeutics Type Outlook (Revenue, USD Billion, 2021 - 2033)
  • Innovative (Branded) Peptides
  • Biosimilar Peptides
  • Generic Peptides
  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Type 2 Diabetes
  • Obesity / Weight Management
  • Neuroendocrine Tumors
  • Acromegaly
  • Growth Hormone Deficiency
  • Prostate Cancer
  • Osteoporosis
  • Breast Cancer (hormone-sensitive)
  • Endometriosis
  • Others
  • Route of Administration Outlook (Revenue, USD Billion, 2021 - 2033)
  • Parenteral
  • Oral
  • Transdermal
  • Nasal
  • Others
  • Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
  • Offline Retail Pharmacies
    • Chain pharmacies
    • Specialty retail pharmacies
    • Independent community pharmacies
  • Online Pharmacies / Telehealth
  • Others (Specialized Peptide Clinics

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
    • 1.1.1. Segment Definitions
  • 1.2. Estimates and Forecast Timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
    • 1.4.5. Details of Primary Research
    • 1.4.6. Research Assumption
  • 1.5. Information or Data Analysis
    • 1.5.1. Data Analysis Models
  • 1.6. Market Formulation & Data Visualization
  • 1.7. Model Details
    • 1.7.1. Commodity Flow Analysis
  • 1.8. Objectives
    • 1.8.1. Objective - 1
    • 1.8.2. Objective - 2
    • 1.8.3. Objective - 3
  • 1.9. List of Secondary Sources
  • 1.10. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. U.S. Peptide Therapeutics (Retail Side) Market
    • 2.1.1. Market Snapshot
    • 2.1.2. Segment Snapshot
      • 2.1.2.1. Therapeutics type & indication segment outlook
      • 2.1.2.2. Route of administration & distribution channel segment outlook
    • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/Ancillary Market Outlook
  • 3.2. Market Trends and Outlook
  • 3.3. Market Dynamics
    • 3.3.1. Market Driver Analysis
    • 3.3.2. Market Restraint Analysis
  • 3.4. Regulatory Framework
  • 3.5. Business Environment Analysis Tools
    • 3.5.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.5.1.1. Supplier power
      • 3.5.1.2. Buyer power
      • 3.5.1.3. Substitution threat
      • 3.5.1.4. Threat of new entrant
      • 3.5.1.5. Competitive rivalry
    • 3.5.2. PESTEL Analysis
  • 3.6. Pricing Analysis in Online vs. Offline Channels
  • 3.7. Consumer Awareness Trends for Peptide Therapies
  • 3.8. Direct-to-Consumer (DTC) Business Models Impact

Chapter 4. Peptide Type Business Analysis

  • 4.1. U.S. Peptide Therapeutics (Retail Side) Market: Peptide Type Movement Analysis
  • 4.2. U.S. Peptide Therapeutics (Retail Side) Market: Peptide Type Segment Dashboard
  • 4.3. Peptide Type Movement & Market Share Analysis, 2024 & 2033
  • 4.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Peptide Type
  • 4.5. GLP-1 Peptides
    • 4.5.1. GLP-1 Peptides Market, 2021 - 2033 (USD Million)
  • 4.6. Wellness/Longevity/Healthspan Peptides
    • 4.6.1. Wellness/Longevity/Healthspan Peptides Market, 2021 - 2033 (USD Million)
  • 4.7. Peptides for Other Acute or Chronic Medical Conditions
    • 4.7.1. Peptides for Other Acute or Chronic Medical Conditions Market, 2021 - 2033 (USD Million)

Chapter 5. Therapeutics Type Business Analysis

  • 5.1. U.S. Peptide Therapeutics (Retail Side) Market: Therapeutics Type Movement Analysis
  • 5.2. U.S. Peptide Therapeutics (Retail Side) Market: Therapeutics Type Segment Dashboard
  • 5.3. Therapeutics Type Movement & Market Share Analysis, 2024 & 2033
  • 5.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Therapeutics Type
  • 5.5. Innovative (Branded) Peptides
    • 5.5.1. Innovative (Branded) Peptides Market, 2021 - 2033 (USD Million)
  • 5.6. Biosimilar Peptides
    • 5.6.1. Biosimilar Peptides Market, 2021 - 2033 (USD Million)
  • 5.7. Generic Peptides
    • 5.7.1. Generic Peptides Market, 2021 - 2033 (USD Million)

Chapter 6. Indication Business Analysis

  • 6.1. U.S. Peptide Therapeutics (Retail Side) Market: Indication Movement Analysis
  • 6.2. U.S. Peptide Therapeutics (Retail Side) Market: Indication Segment Dashboard
  • 6.3. Indication Movement & Market Share Analysis, 2024 & 2033
  • 6.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Indication
  • 6.5. Type 2 Diabetes
    • 6.5.1. Type 2 Diabetes Market, 2021 - 2033 (USD Million)
  • 6.6. Obesity / Weight Management
    • 6.6.1. Obesity / Weight Management Market, 2021 - 2033 (USD Million)
  • 6.7. Neuroendocrine Tumors
    • 6.7.1. Neuroendocrine Tumors Market, 2021 - 2033 (USD Million)
  • 6.8. Acromegaly
    • 6.8.1. Acromegaly Market, 2021 - 2033 (USD Million)
  • 6.9. Growth Hormone Deficiency
    • 6.9.1. Growth Hormone Deficiency Market, 2021 - 2033 (USD Million)
  • 6.10. Prostate Cancer
    • 6.10.1. Prostate Cancer Market, 2021 - 2033 (USD Million)
  • 6.11. Osteoporosis
    • 6.11.1. Osteoporosis Market, 2021 - 2033 (USD Million)
  • 6.12. Breast Cancer (hormone-sensitive)
    • 6.12.1. Breast Cancer (hormone-sensitive) Market, 2021 - 2033 (USD Million)
  • 6.13. Endometriosis
    • 6.13.1. Endometriosis Market, 2021 - 2033 (USD Million)
  • 6.14. Others
    • 6.14.1. Others Market, 2021 - 2033 (USD Million)

Chapter 7. Route of Administration Business Analysis

  • 7.1. U.S. Peptide Therapeutics (Retail Side) Market: Route of Administration Movement Analysis
  • 7.2. U.S. Peptide Therapeutics (Retail Side) Market: Route of Administration Segment Dashboard
  • 7.3. Route of Administration Movement & Market Share Analysis, 2024 & 2033
  • 7.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Route of Administration
  • 7.5. Oral
    • 7.5.1. Oral Market, 2021 - 2033 (USD Million)
  • 7.6. Parenteral
    • 7.6.1. Parenteral Market, 2021 - 2033 (USD Million)
  • 7.7. Transdermal
    • 7.7.1. Transdermal Market, 2021 - 2033 (USD Million)
  • 7.8. Nasal
    • 7.8.1. Nasal Market, 2021 - 2033 (USD Million)
  • 7.9. Other Route of Administration
    • 7.9.1. Other Route of Administration Market, 2021 - 2033 (USD Million)

Chapter 8. Distribution Channel Business Analysis

  • 8.1. U.S. Peptide Therapeutics (Retail Side) Market: Distribution Channel Movement Analysis
  • 8.2. U.S. Peptide Therapeutics (Retail Side) Market: Distribution Channel Segment Dashboard
  • 8.3. Distribution Channel Movement & Market Share Analysis, 2024 & 2033
  • 8.4. U.S. Peptide Therapeutics (Retail Side) Market Estimates & Forecast, by Distribution Channel
  • 8.5. Offline Retail Pharmacies
    • 8.5.1. Offline Retail Pharmacies Market, 2021 - 2033 (USD Million)
    • 8.5.2. Chain Pharmacies
      • 8.5.2.1. Chain Pharmacies Market, 2021 - 2033 (USD Million)
    • 8.5.3. Specialty Retail Pharmacies
      • 8.5.3.1. Specialty Retail Pharmacies market, 2021 - 2033 (USD Million)
    • 8.5.4. Independent Community Pharmacies
      • 8.5.4.1. Specialty Market, 2021 - 2033 (USD Million)
  • 8.6. Online Pharmacies / Telehealth
    • 8.6.1. Online Pharmacies / Telehealth Market, 2021 - 2033 (USD Million)
  • 8.7. Others (Specialized Peptide Clinics)
    • 8.7.1. Others (Specialized Peptide Clinics) Market, 2021 - 2033 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Company Categorization (Offline Pharmacies)
  • 9.2. Company Categorization (Online Pharmacies)
  • 9.3. Company Categorization (Specialized Hormone Clinics)
  • 9.4. Participant's Overview
    • 9.4.1. Offline Pharmacies
    • 9.4.2. Online Pharmacies
    • 9.4.3. Specialized Hormone Clinics
  • 9.5. Company Market Position Analysis
  • 9.6. Strategy Mapping
    • 9.6.1. Regional Expansion
    • 9.6.2. Mergers & Acquisitions
    • 9.6.3. Others
  • 9.7. Company Profiles/Listing
  • 9.8. Offline Pharmacies
    • 9.8.1. CVS Health
      • 9.8.1.1. Overview
      • 9.8.1.2. Financial performance
      • 9.8.1.3. Product benchmarking
      • 9.8.1.4. Strategic initiatives
    • 9.8.2. Walgreens Boots Alliance, Inc.
      • 9.8.2.1. Overview
      • 9.8.2.2. Financial performance
      • 9.8.2.3. Product benchmarking
      • 9.8.2.4. Strategic initiatives
    • 9.8.3. Walmart Pharmacy
      • 9.8.3.1. Overview
      • 9.8.3.2. Financial performance
      • 9.8.3.3. Product benchmarking
      • 9.8.3.4. Strategic initiatives
    • 9.8.4. Rite Aid Corp
      • 9.8.4.1. Overview
      • 9.8.4.2. Financial performance
      • 9.8.4.3. Product benchmarking
      • 9.8.4.4. Strategic initiatives
    • 9.8.5. The Kroger Co.
      • 9.8.5.1. Overview
      • 9.8.5.2. Financial performance
      • 9.8.5.3. Product benchmarking
      • 9.8.5.4. Strategic initiatives
    • 9.8.6. Albertsons
      • 9.8.6.1. Overview
      • 9.8.6.2. Financial performance
      • 9.8.6.3. Product benchmarking
      • 9.8.6.4. Strategic initiatives
    • 9.8.7. Publix
      • 9.8.7.1. Overview
      • 9.8.7.2. Financial performance
      • 9.8.7.3. Product benchmarking
      • 9.8.7.4. Strategic initiatives
    • 9.8.8. Costco Wholesale Corporation
      • 9.8.8.1. Overview
      • 9.8.8.2. Financial performance
      • 9.8.8.3. Product benchmarking
      • 9.8.8.4. Strategic initiatives
    • 9.8.9. Meijer, Inc.
      • 9.8.9.1. Overview
      • 9.8.9.2. Financial performance
      • 9.8.9.3. Product benchmarking
      • 9.8.9.4. Strategic initiatives
  • 9.9. Online Pharmacies
    • 9.9.1. Hims & Hers Health, Inc
      • 9.9.1.1. Overview
      • 9.9.1.2. Financial performance
      • 9.9.1.3. Product benchmarking
      • 9.9.1.4. Strategic initiatives
    • 9.9.2. Ro (Roman Health Ventures Inc.)
      • 9.9.2.1. Overview
      • 9.9.2.2. Financial performance
      • 9.9.2.3. Product benchmarking
      • 9.9.2.4. Strategic initiatives
    • 9.9.3. Lemonaid Health, Inc.
      • 9.9.3.1. Overview
      • 9.9.3.2. Financial performance
      • 9.9.3.3. Product benchmarking
      • 9.9.3.4. Strategic initiatives
    • 9.9.4. Mark Cuban Cost Plus Drug Company, PBC
      • 9.9.4.1. Overview
      • 9.9.4.2. Financial performance
      • 9.9.4.3. Product benchmarking
      • 9.9.4.4. Strategic initiatives
    • 9.9.5. Amazon.com, Inc.
      • 9.9.5.1. Overview
      • 9.9.5.2. Financial performance
      • 9.9.5.3. Product benchmarking
      • 9.9.5.4. Strategic initiatives
    • 9.9.6. Blink Health Administration LLC, Inc.
      • 9.9.6.1. Overview
      • 9.9.6.2. Financial performance
      • 9.9.6.3. Product benchmarking
      • 9.9.6.4. Strategic initiatives
    • 9.9.7. GoodRx, Inc
      • 9.9.7.1. Overview
      • 9.9.7.2. Financial performance
      • 9.9.7.3. Product benchmarking
      • 9.9.7.4. Strategic initiatives
    • 9.9.8. Honeybee Health Inc.
      • 9.9.8.1. Overview
      • 9.9.8.2. Financial performance
      • 9.9.8.3. Product benchmarking
      • 9.9.8.4. Strategic initiatives
    • 9.9.9. TruePill (acquired by LetsGetChecked in October 2024)
      • 9.9.9.1. Overview
      • 9.9.9.2. Financial performance
      • 9.9.9.3. Product benchmarking
      • 9.9.9.4. Strategic initiatives
    • 9.9.10. AgelessRx
      • 9.9.10.1. Overview
      • 9.9.10.2. Financial performance
      • 9.9.10.3. Product benchmarking
      • 9.9.10.4. Strategic initiatives
  • 9.10. Specialized Hormone Clinics
    • 9.10.1. Defy Medical
      • 9.10.1.1. Overview
      • 9.10.1.2. Financial performance
      • 9.10.1.3. Product benchmarking
      • 9.10.1.4. Strategic initiatives
    • 9.10.2. Renew Vitality
      • 9.10.2.1. Overview
      • 9.10.2.2. Financial performance
      • 9.10.2.3. Product benchmarking
      • 9.10.2.4. Strategic initiatives
    • 9.10.3. Victory Men's Health
      • 9.10.3.1. Overview
      • 9.10.3.2. Financial performance
      • 9.10.3.3. Product benchmarking
      • 9.10.3.4. Strategic initiatives
    • 9.10.4. Hone Health
      • 9.10.4.1. Overview
      • 9.10.4.2. Financial performance
      • 9.10.4.3. Product benchmarking
      • 9.10.4.4. Strategic initiatives
    • 9.10.5. Joi & Blokes
      • 9.10.5.1. Overview
      • 9.10.5.2. Financial performance
      • 9.10.5.3. Product benchmarking
      • 9.10.5.4. Strategic initiatives
    • 9.10.6. Ways2Well
      • 9.10.6.1. Overview
      • 9.10.6.2. Financial performance
      • 9.10.6.3. Product benchmarking
      • 9.10.6.4. Strategic initiatives
    • 9.10.7. 4Ever Young Anti-aging Solutions
      • 9.10.7.1. Overview
      • 9.10.7.2. Financial performance
      • 9.10.7.3. Product benchmarking
      • 9.10.7.4. Strategic initiatives
    • 9.10.8. T CLINICS USA
      • 9.10.8.1. Overview
      • 9.10.8.2. Financial performance
      • 9.10.8.3. Product benchmarking
      • 9.10.8.4. Strategic initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Market size & forecasts and trend analysis for the therapeutics type segment, 2021 - 2033 (USD Million)
  • Table 4 Market size & forecasts and trend analysis for the indication segment, 2021 - 2033 (USD Million)
  • Table 5 Market size & forecasts and trend analysis for the route of administration segment, 2021 - 2033 (USD Million)
  • Table 6 Market size & forecasts and trend analysis for the distribution channel segment, 2021 - 2033 (USD Million)
  • Table 7 Market size & forecasts and trend analysis for the offline retail pharmacies type segment, 2021 - 2033 (USD Million)

List of Figures

  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Indication segment snapshot
  • Fig. 10 Route of administration & therapeutics type segment snapshot
  • Fig. 11 Distribution channel segment snapshot
  • Fig. 12 Competitive landscape
  • Fig. 13 U.S. pharmacy market value, 2024 (USD Billion)
  • Fig. 14 U.S. peptide therapeutics (retail side) market dynamics
  • Fig. 15 U.S. peptide therapeutics (retail side) market: Porter's five forces analysis
  • Fig. 16 U.S. peptide therapeutics (retail side) market: PESTLE analysis
  • Fig. 17 U.S. peptide therapeutics (retail side) market therapeutics type outlook: Segment dashboard
  • Fig. 18 U.S. peptide therapeutics (retail side) market: Therapeutics type movement & market share analysis, 2024 & 2033
  • Fig. 19 Innovative (branded) peptides market, 2021 - 2033 (USD Billion)
  • Fig. 20 Generic peptides market, 2021 - 2033 (USD Billion)
  • Fig. 21 Biosimilar peptides market, 2021 - 2033 (USD Billion)
  • Fig. 22 U.S. peptide therapeutics (retail side) market indication outlook: Segment dashboard
  • Fig. 23 U.S. peptide therapeutics (retail side) market: Indication movement & market share analysis, 2024 & 2033
  • Fig. 24 Type 2 diabetes market, 2021 - 2033 (USD Billion)
  • Fig. 25 Obesity/weight management market, 2021 - 2033 (USD Billion)
  • Fig. 26 Prostate cancer market, 2021 - 2033 (USD Billion)
  • Fig. 27 Breast cancer (hormone-sensitive) market, 2021 - 2033 (USD Billion)
  • Fig. 28 Endometriosis market, 2021 - 2033 (USD Billion)
  • Fig. 29 Growth hormone deficiency market, 2021 - 2033 (USD Billion)
  • Fig. 30 Acromegaly market, 2021 - 2033 (USD Billion)
  • Fig. 31 Osteoporosis market, 2021 - 2033 (USD Billion)
  • Fig. 32 Neuroendocrine tumors market, 2021 - 2033 (USD Billion)
  • Fig. 33 Others market, 2021 - 2033 (USD Billion)
  • Fig. 34 U.S. peptide therapeutics (retail side) market route of administration outlook: Segment dashboard
  • Fig. 35 U.S. peptide therapeutics (retail side) market: Route of administration movement & market share analysis, 2024 & 2033
  • Fig. 36 Oral market, 2021 - 2033 (USD Billion)
  • Fig. 37 Parenteral market, 2021 - 2033 (USD Billion)
  • Fig. 38 Transdermal market, 2021 - 2033 (USD Billion)
  • Fig. 39 Nasal market, 2021 - 2033 (USD Billion)
  • Fig. 40 Others market, 2021 - 2033 (USD Billion)
  • Fig. 41 U.S. peptide therapeutics (retail side) market distribution channel outlook: Segment dashboard
  • Fig. 42 U.S. peptide therapeutics (retail side) market: Distribution channel movement & market share analysis, 2024 & 2033
  • Fig. 43 Offline retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 44 Chain pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 45 Independent community pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 46 Specialty retail pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 47 Online pharmacies market, 2021 - 2033 (USD Billion)
  • Fig. 48 Others (specialized peptide clinics) market, 2021 - 2033 (USD Billion)
  • Fig. 49 Company categorization (Offline Pharmacies)
  • Fig. 50 Company categorization (Online Pharmacy)
  • Fig. 51 Company categorization (Specialized Clinics)
  • Fig. 52 Company market position analysis
  • Fig. 53 Company market position analysis
  • Fig. 54 Company market position analysis
  • Fig. 55 Strategic framework